Scalper1 News
Biotech Insys Therapeutics (INSY) soundly beat analysts’ Q4 estimates and announced a stock split Tuesday, sending shares soaring more than 20% to a new high on the stock market today. The company’s revenue totaled $40 million in the quarter vs. just $5 million in the year-earlier quarter, as sales of its pain medicine Subsys ramped quickly from its March 2012 launch. Analysts had expected $35 million on average. Profit totaled 71 cents a share, Scalper1 News
Scalper1 News